PMID- 28714741
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20221207
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 12
DP  - 2017 Aug
TI  - The efficacy and safety of adding either vildagliptin or glimepiride to ongoing 
      metformin therapy in patients with type 2 diabetes mellitus.
PG  - 1179-1186
LID - 10.1080/14656566.2017.1353080 [doi]
AB  - OBJECTIVE: To compare the effects of either vildagliptin or glimepiride on 
      glycemic variability, oxidative stress, and endothelial parameters in patients 
      with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin 
      alone. METHODS: In this randomized, open-label, parallel study, 34 patients with 
      T2DM being treated with metformin having an HbA1c of 7.0-10.0% were allocated 
      into either the vildagliptin or glimepiride group. A mixed-meal tolerance test 
      and 72-hour continuous glucose monitoring were conducted, and urinary 
      8-iso-prostaglandinF(2alpha) (PGF(2alpha)) and endothelial-dependent flow-mediated 
      dilatation (FMD) were evaluated at baseline and after 12 weeks of treatment. 
      RESULTS: Similar significant improvements in HbA1c level were shown in both 
      vildagliptin (-0.8%) and glimepiride (-0.9%) groups after treatment (Ps<0.001). 
      The mean amplitude of glycemic excursions (MAGE) and the mean of daily 
      differences (MODD) were significantly decreased by vildagliptin (P = 0.044 and 
      P = 0.031, respectively) but not by glimepiride. Glimepiride was significantly 
      associated with a higher incidence of hypoglycemia than vildagliptin (P = 0.005). 
      There were no significant differences in urinary 8-iso-PGF(2alpha) or FMD between the 
      two groups. CONCLUSIONS: Vildagliptin effectively improved glucose level with a 
      significantly greater reduction in glycemic variability and hypoglycemia than 
      glimepiride in patients with T2DM ongoing metformin therapy. The two drugs showed 
      no significant differences in urinary 8-iso-PGF(2alpha) and FMD. TRIAL REGISTRATION: 
      NCT01404676.
FAU - Kim, Gyuri
AU  - Kim G
AD  - a Division of Endocrinology and Metabolism, Department of Medicine , Samsung 
      Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of 
      Korea.
FAU - Oh, Sewon
AU  - Oh S
AD  - a Division of Endocrinology and Metabolism, Department of Medicine , Samsung 
      Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of 
      Korea.
FAU - Jin, Sang-Man
AU  - Jin SM
AD  - a Division of Endocrinology and Metabolism, Department of Medicine , Samsung 
      Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of 
      Korea.
FAU - Hur, Kyu Yeon
AU  - Hur KY
AD  - a Division of Endocrinology and Metabolism, Department of Medicine , Samsung 
      Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of 
      Korea.
FAU - Kim, Jae Hyeon
AU  - Kim JH
AD  - a Division of Endocrinology and Metabolism, Department of Medicine , Samsung 
      Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of 
      Korea.
FAU - Lee, Moon-Kyu
AU  - Lee MK
AD  - a Division of Endocrinology and Metabolism, Department of Medicine , Samsung 
      Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of 
      Korea.
LA  - eng
SI  - ClinicalTrials.gov/NCT01404676
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170717
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - 6KY687524K (glimepiride)
RN  - 9100L32L2N (Metformin)
RN  - B7IN85G1HY (Dinoprost)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dinoprost/analogs & derivatives/urine
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Metformin/administration & dosage/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Nitriles/administration & dosage/adverse effects/*therapeutic use
MH  - Pyrrolidines/administration & dosage/adverse effects/*therapeutic use
MH  - Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Vildagliptin
OTO - NOTNLM
OT  - Continuous glucose monitoring
OT  - flow-mediated dilatation
OT  - glimepiride
OT  - mixed-meal tolerance test
OT  - oxidative stress
OT  - type 2 diabetes
OT  - vildagliptin
EDAT- 2017/07/18 06:00
MHDA- 2017/11/07 06:00
CRDT- 2017/07/18 06:00
PHST- 2017/07/18 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
PHST- 2017/07/18 06:00 [entrez]
AID - 10.1080/14656566.2017.1353080 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Aug;18(12):1179-1186. doi: 
      10.1080/14656566.2017.1353080. Epub 2017 Jul 17.